After Remdesivir's Emergency Use Authorization, US Gov't Must Now Decide How To Distribute Limited Supply
Gilead's antiviral remdesivir will go to hospitalized severe COVID-19 patients per FDA's EUA. Some cities could receive the medicine with days, but it is not clear how the government will dole out the limited supplies. FDA said it had access to non-public data from a key NIH trial during its EUA review.
You may also be interested in...
Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.
The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.
Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.